National Cancer Institute; Notice of Closed Meeting, 16106 [2020-05817]

Download as PDF 16106 Federal Register / Vol. 85, No. 55 / Friday, March 20, 2020 / Notices The meeting format has changed from an in-person meeting to a teleconference. The meeting is closed to the public. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: March 16, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. National Heart, Lung, and Blood Institute; Amended Notice of Meeting [FR Doc. 2020–05821 Filed 3–19–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. jbell on DSKJLSW7X2PROD with NOTICES Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Infectious Diseases. Date: March 23–24, 2020. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting). Contact Person: Alexander D. Politis, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3210, MSC 7808, Bethesda, MD 20892, (301) 435– 1150, politisa@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 16, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05814 Filed 3–19–20; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 19:01 Mar 19, 2020 Jkt 250001 National Institutes of Health Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis Panel, April 14, 2020, 08:30 a.m. to April 14, 2020, 04:00 p.m., The William F. Bolger Center, 9600 New Bridge Drive, Potomac, MD 20854 which was published in the Federal Register on March 04, 2020, 85 FR 12799. The NHLBI Special Emphasis Panel meeting is being amended due to a change in the meeting format. This one day meeting to be held on April 14, 2020 will be a teleconference meeting. The meeting is closed to the public. Dated: March 16, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05819 Filed 3–19–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Name of Committee: National Cancer Institute Special Emphasis Panel; FEB2020 Cycle 34 NExT SEP Committee Meeting. Date: April 21, 2020. Time: 9:00 a.m. to 3:00 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Room 3A44, Bethesda, MD 20892, Teleconference Call. Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496–4291, mroczkoskib@mail.nih.gov; Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH 9609, Medical Center Drive, Room 3W110, Rockville, MD 20850, (240) 276–5683, toby.hecht2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: March 16, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05817 Filed 3–19–20; 8:45 am] National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. PO 00000 Frm 00060 Fmt 4703 Sfmt 9990 BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, RM18– 009: NIH Transformative Research Awards (R01) Review, April 7, 2020, 8:00 a.m. to 6:00 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814, which was published in the Federal Register on March 13, 2020, 85 FR 14687. The meeting will be held at National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20872. The meeting date remains the same. The meeting is closed to the public. Dated: March 16, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05815 Filed 3–19–20; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\20MRN1.SGM 20MRN1

Agencies

[Federal Register Volume 85, Number 55 (Friday, March 20, 2020)]
[Notices]
[Page 16106]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-05817]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for the treatment of cancer. The outcome of the evaluation will provide 
information to internal NCI committees that will decide whether NCI 
should support requests and make available contract resources for 
development of the potential therapeutic to improve the treatment of 
various forms of cancer. The research proposals and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; FEB2020 Cycle 34 NExT SEP Committee Meeting.
    Date: April 21, 2020.
    Time: 9:00 a.m. to 3:00 p.m.
    Agenda: To evaluate the NCI Experimental Therapeutics Program 
Portfolio.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, Room 3A44, Bethesda, MD 20892, Teleconference Call.
    Contact Persons: Barbara Mroczkowski, Ph.D., Executive 
Secretary, Discovery Experimental Therapeutics Program, National 
Cancer Institute, NIH 31 Center Drive, Room 3A44, Bethesda, MD 
20817, (301) 496-4291, [email protected]; Toby Hecht, Ph.D., 
Executive Secretary, Development Experimental Therapeutics Program, 
National Cancer Institute, NIH 9609, Medical Center Drive, Room 
3W110, Rockville, MD 20850, (240) 276-5683, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: March 16, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-05817 Filed 3-19-20; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.